Screener
Zymeworks ZYME Reportable Segment — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Zymeworks in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Zymeworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001937653-26-000047
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| ZW191 | 3,127 | 2,764 | 6,158 | 4,470 |
| ZW220 | (152) | 327 | (55) | 2,525 |
| ZW251 | 3,205 | 2,340 | 5,112 | 6,291 |
| Expense for other preclinical and research programs | 4,192 | 6,174 | 11,456 | 12,250 |
| Unallocated research and development expenses: | ||||
| Salaries and benefits and stock based compensation | 10,681 | 12,034 | 25,440 | 24,757 |
| Other research and development expense | 4,659 | 5,987 | 10,285 | 11,440 |
| Total research and development expenses | $27,435 | $34,449 | $61,892 | $70,187 |
Item 1. Financial Statements
FAQ
- What is Zymeworks's reportable segment — R&D?
- Zymeworks (ZYME) reported reportable segment — R&D of $27.44M in Q2 2026.
- What does reportable segment — R&D mean?
- This metric aggregates all costs associated with the research and development activities of the reportable segment, including clinical trials, laboratory operations, and platform development. It is a primary measure of the company's commitment to advancing its therapeutic pipeline and innovation engine.
Ask your AI about Zymeworks's reportable segment — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude